GPR158 Antibody

What are the optimal applications for GPR158 antibody detection?

GPR158 antibodies have been successfully validated for multiple applications with varying optimal concentrations:

• Western Blotting: 1-25 μg/mL, depending on the specific antibody clone and sample type. Most effective for detecting the ~175-191 kDa GPR158 protein band under reducing conditions .

• Immunohistochemistry: 5-25 μg/mL for paraffin-embedded tissue sections, particularly effective in human brain cortex tissue where GPR158 localizes to neuronal cytoplasm .

• Flow Cytometry: 0.25 μg per 10^6 cells, optimal for transfected cell lines expressing GPR158 .

• Immunofluorescence: 8 μg/mL for fixed cell lines, with incubation time of approximately 3 hours at room temperature .

• ELISA: Concentration requirements vary by antibody format; both unconjugated and conjugated (HRP, biotin) formats are available .

What tissue and cell types are recommended for GPR158 antibody validation?

Based on published research, the following samples provide reliable GPR158 detection:

• Brain tissue: Human brain cortex shows robust GPR158 expression, particularly in neuronal cytoplasm .

• Cell lines:

  • HEK293T cells transfected with GPR158 serve as an excellent positive control .

  • T47D human breast cancer cells show endogenous membrane localization of GPR158 .

  • COS1 cells are suitable for live-cell GPR158 antibody staining protocols .

What epitope regions of GPR158 are targeted by commonly available antibodies?

Commercial antibodies target several distinct regions of GPR158:

• N-terminal domain: Antibodies targeting AA 1-50 or Ala24-Gln411 regions are available as both monoclonal (clone #1027604, clone #1027651) and polyclonal formats .

• C-terminal domain: Several antibodies target regions between AA 882-1003 or AA 1120-1169 .

• Domain-specific antibodies: Specialized antibodies against GPR158 N-terminus (GPR158NT) and C-terminus (GPR158CT) have been used in research settings for different applications (live staining versus western blotting) .

How should GPR158 knockdown experiments be designed and validated?

For effective GPR158 knockdown:

• siRNA design: Use a pool of at least three custom-designed siRNA oligonucleotides targeting GPR158. Confirm specificity via BLAST search to avoid off-target effects .

• Modification strategy: Consider 2′-O-methyl modification at position 2 to further reduce off-target activity while maintaining silencing efficacy .

• Concentration optimization: Test concentration-dependent effects; published protocols show 80-90% knockdown efficiency at 100 nM siRNA concentration .

• Controls: Include both scrambled control siRNA with matching GC% content and monitor housekeeping proteins (like actin) to confirm specificity .

• Validation: Perform both protein-level validation (western blot) and mRNA-level validation (qRT-PCR) to confirm knockdown efficiency .

What protocols are recommended for GPR158 detection in fixed tissue samples?

For optimal GPR158 immunohistochemistry in fixed tissues:

• Fixation: Use immersion fixation with 4% paraformaldehyde for tissue sections .

• Antigen retrieval: Perform heat-induced epitope retrieval using basic antigen retrieval reagents (like CTS013) prior to antibody incubation .

• Antibody concentration: Apply primary GPR158 antibody at 5-25 μg/mL for 1 hour at room temperature .

• Detection system: For chromogenic detection, use anti-mouse IgG HRP polymer antibody systems followed by DAB (brown) visualization and hematoxylin counterstaining .

• Controls: Include tissues with known GPR158 expression (cortical neurons) as positive controls .

What are the recommended protocols for live-cell GPR158 staining?

For successful live-cell staining of GPR158:

• Antibody selection: Use antibodies targeting the extracellular N-terminal domain of GPR158 (such as anti-GPR158 from Assay Biotech) .

• Incubation conditions: Incubate live cells with the anti-GPR158 antibody at 4°C overnight in PBS containing 2% donor serum .

• Post-staining processing: After brief washing, fix cells with 4% paraformaldehyde (15 min), then permeabilize with 0.1% Triton X-100 for 5 minutes .

• Secondary detection: Apply fluorescent secondary antibodies (e.g., Alexa Fluor 488) in 2% serum for 1 hour .

• Nuclear counterstaining: Use DAPI for 5 minutes before mounting in appropriate medium (e.g., Fluoromount G) .

• Imaging: Visualize using confocal microscopy with appropriate laser settings to detect membrane localization .

How can specificity of GPR158 antibody signals be validated?

To confirm GPR158 antibody specificity:

• Positive controls: Use HEK293T cells transfected with human GPR158 alongside mock-transfected controls .

• Knockout/knockdown validation: Compare antibody staining between wild-type and Gpr158−/− samples or siRNA-treated cells with >80% protein reduction .

• Multiple antibody approach: Validate findings using antibodies targeting different epitopes of GPR158 (N-terminal vs. C-terminal) .

• Expected molecular weight confirmation: Verify detection of the correct band size (~175-191 kDa) in western blot applications .

• Subcellular localization consistency: Confirm appropriate localization patterns (membrane and/or cytoplasmic, depending on cell type and fixation method) .

How can GPR158 antibody performance be optimized for challenging samples?

For improved GPR158 detection in difficult samples:

• Signal amplification: For low expression samples, consider using polymer-based detection systems like VisUCyte HRP for IHC or fluorescent secondary antibodies with higher sensitivity for IF .

• Epitope retrieval optimization: Test multiple antigen retrieval methods (heat-induced vs. enzymatic) and pH conditions (basic vs. acidic) to maximize epitope accessibility .

• Blocking optimization: Extend blocking time (1+ hours) with higher serum concentration (10%) to reduce background in high-background tissues .

• Antibody incubation: Extend primary antibody incubation time (overnight at 4°C) for weaker signals while maintaining specificity .

• Sample preparation: For membrane proteins like GPR158, ensure proper membrane permeabilization without disrupting epitope integrity .

How can GPR158 antibodies be used to study GPR158-RGS7 complex formation?

To investigate GPR158-RGS7 interactions:

• Co-immunoprecipitation: Use anti-GPR158 antibodies to immunoprecipitate the protein complex, followed by western blotting with anti-RGS7 antibodies. Reciprocal experiments (IP with anti-RGS7, WB with anti-GPR158) confirm specificity .

• Domain mapping: Utilize truncated GPR158 constructs (GPR158-FL, GPR158-ΔCD4, GPR158-ΔCD1/2/3) to identify which domains are essential for RGS7 binding .

• Gβ5 dependency analysis: Include experiments with and without Gβ5 to determine its requirement for complex formation .

• DEP domain analysis: Compare binding of wild-type RGS7 versus DEPless RGS7 to confirm domain-specific interactions .

• Subcellular localization: Perform co-localization studies using confocal microscopy with differentially labeled antibodies against GPR158 and RGS7 .

What are the methodological considerations for studying GPR158 in disease models?

When investigating GPR158 in disease contexts:

• Cancer studies:

  • For prostate cancer research, focus on androgen receptor co-localization and function during androgen deprivation therapy .

  • In glioma studies, correlate GPR158 expression with molecular subtypes and patient survival data .

  • For melanoma, examine GPR158 hypermethylation status alongside protein expression levels .

• Neuropsychiatric models:

  • In depression models, quantify GPR158 expression changes in response to chronic stress using IHC and western blot .

  • Compare Gpr158−/− mouse behavior with GPR158 antibody-based tissue analysis .

• Aging and neurodegeneration:

  • For age-related memory loss studies, track GPR158 expression changes across age groups .

  • In Parkinson's disease models, examine neuron-specific GPR158 expression patterns .

• Ocular studies:

  • For glaucoma research, focus on GPR158 expression in ocular tissues related to intraocular pressure regulation .

How can cryo-EM structural data inform GPR158 antibody epitope selection?

Recent structural insights can guide antibody selection:

• Domain-targeted approach: Select antibodies targeting specific structural domains identified in cryo-EM studies:

  • Per-Arnt-Sim-fold extracellular domain

  • Epidermal growth factor-like linker region

  • Transmembrane domain interfaces (particularly TM4/5)

  • Intracellular loops (ICL2, ICL3) involved in RGS7 binding

• Dimerization interface consideration: Choose antibodies that either target or avoid the dimerization interface depending on whether monomeric or dimeric GPR158 is being studied .

• RGS7-binding platform: For studying GPR158-RGS7 interactions, select antibodies that don't interfere with the ICL2, ICL3, TM3, and cytoplasmic coiled-coil regions that form the RGS7-binding platform .

• Conformation-specific antibodies: Consider developing antibodies that selectively recognize active versus inactive conformational states of the transmembrane domain .

How can GPR158 antibodies be utilized in neuro-immune crosstalk studies?

For investigating GPR158's role in neuro-immune interactions:

• SNP-specific analysis: Design approaches correlating GPR158 SNPs with immune responses in vaccination or viral clearance models using antibodies for protein expression analysis .

• Co-localization with immune markers: Perform dual immunofluorescence with GPR158 antibodies and immune cell markers in neuroinflammatory conditions .

• Cytokine response correlation: Measure GPR158 expression changes in response to inflammatory cytokines in neuronal cultures .

• Microglial interaction studies: Investigate potential GPR158 expression in microglia or its role in neuron-microglia communication using cell-type specific markers alongside GPR158 antibodies .

What methodological approaches can reveal the relationship between GPR158 and OCN signaling?

To study the osteocalcin (OCN)-GPR158 signaling axis:

• Binding assays: Develop co-immunoprecipitation or proximity ligation assays using anti-GPR158 antibodies to detect potential OCN binding .

• Functional readouts: Combine GPR158 antibody staining with downstream signaling markers (IP3, BDNF) in response to OCN treatment .

• Knockout validation: Compare OCN responses in wild-type versus Gpr158−/− tissues using GPR158 antibodies to confirm knockout efficiency .

• Tissue-specific expression: Map GPR158 expression in tissues responsive to OCN (brain, adrenal gland) using immunohistochemistry .

• Signaling pathway characterization: Use phospho-specific antibodies for downstream effectors alongside GPR158 antibodies to map the complete signaling cascade .